There are some good headline numbers in that report, but there are also some good numbers & other info hidden in parts of the report that you need to do a bit more digging for.
- Infusions was profitable to the tune of $1.2M, or a 7.8% Margin
- We are currently sitting on $4.45M of Inventory (which is presumably a lot of high margin consumables for nRAH and high margin Adapt) - if we assume that on average inventory has 50% G.P, it grosses up to $8.9M of future revenue where the COS has already been paid for in prior periods. (good for cash conversion in upcoming periods).
- *Trade Receivables were $3255K (good headstart for cash collections this Q), but trade payables were only $1962K
*Excludes ~$1M related to a Townsville Hospital contract that is converted to cash sporadically.
- Rodne & the Other Ex-Directors have completely sold out (no more relentless selling from people with an axe to grind)
- The CFO of the company (ex Cochlear) took 20% of his ex-super wage as share based payments.
- 'it is appropriate to adopt the going concern basis in the preparation of the financial report after consideration of the following factors: New markets for the Groups ADAPT® products including India, Australia, Philippines, Taiwan, Vietnam, Spain, Hungary, Baltics and Mexico'
Looking forward to some more info from the webinar on Tues!
Add to My Watchlist
What is My Watchlist?
